The rapid rise of artificial intelligence (AI) and machine learning (ML) in biotechnology products and services is becoming a driver of the personalized medicine and health care sectors. While this integration can require special consideration during development of a patent portfolio, stakeholders across engineering, legal, and executive teams in both established companies and start-ups can leverage it to create valuable intellectual property (IP) assets in the marketplace.
Medicare telehealth post-Public Health Emergency (PHE): With the COVID-19 PHE concluding on May 11, 2023, many of the telehealth flexibilities the Centers for Medicare & Medicaid Services (CMS) implemented during the PHE will sunset at varying times.
Between now and 2030, the biopharma sector is expected to be rocked by a number of high-profile patent cliffs that are likely to reshape the market in potentially unpredictable ways. A “patent cliff” refers to the end of IP protection for a drug that has enjoyed market exclusivity since its launch.
Although use of telehealth in clinical trials is not new, the modality was not popularized until social distancing efforts brought about by COVID-19 forced the issue. Companies interested in providing clinical trial services via telehealth have to deal with whether the carrying out the clinical aspects of a clinical trial is part of the practice of medicine.
The presence of private equity (PE) investment has exploded in recent years in all areas of the health care sector. PE in health care is a good thing when done right: It can pave the way for much needed innovation, efficiency, and nontraditional care delivery models. However, government regulators, media journalists, some health care practitioners, and private parties are watching PE investment with growing suspicion that profit-driven goals may conflict with the quality of care for patients.
The COVID-19 pandemic forever changed employer-employee relations and rendered conventional perspectives on where, when, and how work is performed antiquated. As the COVID-19 pandemic turns into an endemic, the workplace issues and operational initiatives that have consumed the corporate world’s attention are likewise shifting. This article discusses what has changed and key lessons learned along the way.
Many complex and large lawsuits end up in mediation. However, because of various characteristics of securities class actions, including the law and procedures that are applicable to securities claims and the way the insurance is generally structured, it is difficult to manage mediations of these cases. This article discusses some of these challenges.
Bankruptcies – even when they’re not your own – can stretch you financially. Even though you don’t control the financial health of your business partners, you can control whether you’re prepared to maximize your recovery and minimize the financial harm to your business. This article outlines some tips to better position your business to do exactly that.
The coronavirus pandemic, the U.S.-China trade war, and the war in Ukraine have accelerated the transformation of the world's global supply chains. These developments have prompted organizations to search for a closer, more reliable supply chain that is less dependent on transoceanic transportation. This article discusses considerations for foreign companies choosing Mexico as a nearshoring option.
This ACC Guide sponsored by Kilpatrick Townsend & Stockton LLP provides an overview of five specific aspects of brand protection and enhancement in the United States.